Humanetics Corporation (Humanetics) announced today that it has received funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to conduct a study of its drug, BIO 300, in COVID-19 patients. The study will focus on patients who were treated for severe COVID-19 disease, many of whom were discharged from the hospital and are recuperating at home. These patients face the possible risk that their respiratory complications will continue to progress, leading to long-term impairment of lung function.